Letter From Egom Regarding Article, “High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy”
To the Editor:
In their recent article, Mora et al1 reported that the on-treatment number of high-density lipoprotein (HDL) particles (HDL-P) may be a better marker of residual risk than HDL cholesterol or apolipoprotein A-I.
Although this observation makes a valuable contribution to this field, it is important to emphasize that HDL-P may only give us a small part of the overall HDL picture. Furthermore, some of Mora et al.’s findings must be interpreted with caution because of the potential effect of rosuvastatin on …